Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): Evolution and prognostic impact

被引：0

作者：

Diaz-Guardamino, I. Echavarria ^{[1
]}

Lopez-Tarruella Cobo, S. ^{[2
]}

Del Monte-Millan, M. ^{[2
]}

Alvarez, E. ^{[2
]}

Jerez Gilarranz, Y. ^{[2
]}

Moreno Anton, F. ^{[3
]}

Garcia Saenz, J. A. ^{[4
]}

Massarrah, T. ^{[1
]}

Ocana, I. ^{[5
]}

Cebollero, M. ^{[6
]}

Ballesteros Garcia, A. I. ^{[7
]}

Bohn Sarmiento, U. ^{[8
]}

Gomez, H. ^{[9
]}

Fuentes Rivera, H. ^{[10
]}

Herrero Lopez, B. ^{[11
]}

Polo, C. ^{[12
]}

Bueno, O. ^{[13
]}

Rahimi, P. ^{[5
]}

Bueno Muino, C. ^{[14
]}

Martin Jimenez, M. ^{[15
]}

机构：

[1] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, Inst Invest Sanitaria Gregorio Maranon, CiberOnc, Madrid, Spain

[2] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, CIBERONC ISCIII, GEICAM,Spanish Breast Canc Grp, Madrid, Spain

[3] Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain

[4] Hosp Clin San Carlos IdISSC, Inst Invest Sanitaria, CIBERONC, Med Oncol Dept, Madrid, Spain

[5] Inst Invest Sanitaria GregorioMaranon, Dept Med Oncol, Madrid, Spain

[6] Hosp Gen Univ Gregorio Maranon, Pathol, Madrid, Spain

[7] Hosp Univ Princesa, Dept Med Oncol, Madrid, Spain

[8] Hosp Univ Gran Canaria Doctor Negrin, Dept Med Oncol, Las Palmas Gran Canaria, Canary Island, Spain

[9] Oncosalud SAC, Radioncol Dept, Lima, Peru

[10] Aliada Canc, Ctr Oncol, Dept Med Oncol, Lima, Peru

[11] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain

[12] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain

[13] Hosp Gen Univ Gregorio Maranon, Radiol, Madrid, Spain

[14] Hosp Sur, Med Oncol, Madrid, Spain

[15] Hosp Gen Univ Gregorio Maranon, Med Dept, Serv Oncol, Madrid, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.204

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

261P

引用

页码：S324 / S325

页数：2

共 50 条

[1] Ultrasound assessment of residual disease after neoadjuvant chemotherapy (NACT) in node positive triple negative breast cancer (TNBC)
Adrada, B. E.
Valero, V.
Reddy, S. M.
Barcenas, C. H.
Candelaria, R.
Wei, W.
Rauch, G. M.
CANCER RESEARCH, 2019, 79 (04)
[2] Characteristics of residual tumor after neoadjuvant chemotherapy (nact) may predict outcomes in patients with triple negative breast cancer (tnbc)
Frolova, M.
Glazkova, E.
Petrovsky, A.
Rumyantsev, A.
Stenina, M.
Tjulandin, S.
BREAST, 2023, 68 : S58 - S58
[3] The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
Abuhadra, Nour
Chang, Chia-Chi
Yam, Clinton
White, Jason B.
Ravenberg, Elizabeth
Lim, Bora
Ueno, Naoto T.
Litton, Jennifer Keating
Arun, Banu
Damodaran, Senthil
Murthy, Rashmi Krishna
Ibrahim, Nuhad K.
Hortobagyi, Gabriel N.
Valero, Vicente
Tripathy, Debu
Thompson, Alastair Mark
Mittendorf, Elizabeth A.
Huo, Lei
Moulder, Stacy L.
Jenq, Robert R.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Prognostic Impact of Residual Disease After Neoadjuvant Chemotherapy in 648 Patients with Triple-negative Breast Cancer
Kern, Peter
Von Minckwitz, Gunter
Puetter, Carolin
Pavlidou, Sofia
Flach, Annika
Kimmig, Rainer
Rezai, Mahdi
ANTICANCER RESEARCH, 2015, 35 (10) : 5479 - 5484
[5] Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
Li, Zhijun
Han, Yiqun
Wang, Jiayu
Xu, Binghe
JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (02):
[6] Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study
Khoury, K.
Isaacs, C.
Gatti-Mays, M. E.
Donahue, R. N.
Schlom, J.
Wang, H.
Gallagher, C.
Graham, D.
Warren, R.
Dilawari, A.
Swain, S. M.
Pohlmann, P. R.
Lynce, F.
CANCER RESEARCH, 2019, 79 (04)
[7] Biomarker identification of residual triple negative breast cancer (TNBC) after standard neoadjuvant chemotherapy (NCT)
Sohn, Joohyuk
Liu, Shuyling
Chen, Huiqin
Meng, Xiaolong
Kim-Anh Do
Mills, Gordon B.
Hortobagyi, Gabriel N.
Meric-Bernstam, Funda
Gonzalez-Angulo, Ana M.
CANCER RESEARCH, 2012, 72
[8] Trends, patterns, and outcomes of neoadjuvant chemotherapy (NACT) use among patients with early invasive triple negative breast cancer (TNBC)
Jackson, Inimfon
Lei, Xiudong
Malinowski, Catalina
Giordano, Sharon H.
Chavez-MacGregor, Mariana
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes
Basho, Reva K.
Trevarton, Alex
Hess, Kenneth R.
Fu, Chunxiao
Lau, Rosanna
Lin, Chih-Hsu
Lichtarge, Olivier
Yang, Wei Tse
Symmans, William Fraser
Moulder, Stacy L.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
Hall, C.
Hess, R.
Ravenberg, L.
Clayborn, A.
Rauch, G. M.
Candelaria, R.
Mittendorf, E. A.
Moulder, S. L.
Thompson, A.
Lucci, A.
ANNALS OF ONCOLOGY, 2018, 29

← 1 2 3 4 5 →